Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 619,061 shares, a growth of 125.8% from the January 15th total of 274,164 shares. Approximately 44.2% of the company’s shares are short sold. Based on an average daily volume of 13,995,251 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 13,995,251 shares, the days-to-cover ratio is currently 0.0 days. Approximately 44.2% of the company’s shares are short sold.

Analysts Set New Price Targets

Several research analysts have recently issued reports on SHPH shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised shares of Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Shuttle Pharmaceuticals has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Price Performance

Shuttle Pharmaceuticals stock opened at $1.03 on Friday. The stock’s 50 day moving average is $1.78 and its 200 day moving average is $2.73. Shuttle Pharmaceuticals has a one year low of $1.03 and a one year high of $17.70. The firm has a market cap of $1.65 million, a P/E ratio of -0.09 and a beta of -1.02.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings results on Thursday, November 13th. The company reported ($1.05) earnings per share (EPS) for the quarter.

Institutional Trading of Shuttle Pharmaceuticals

A hedge fund recently bought a new stake in Shuttle Pharmaceuticals stock. Geode Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 14,444 shares of the company’s stock, valued at approximately $26,000. Geode Capital Management LLC owned 0.90% of Shuttle Pharmaceuticals at the end of the most recent quarter. 4.58% of the stock is owned by hedge funds and other institutional investors.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .